🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Calgary
Clinical trial register · Canada

Clinical Trials in Calgary, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Edmonton 39 Calgary 37 Toronto 28 Montreal 24 London 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Calgary148 AstraZeneca62 AbbVie37 Janssen Research & Development, LLC30 National Cancer Institute (NCI)27 Clear sponsor filter
Site location
Edmonton39 Calgary37 Toronto28 Montreal24 London18
All 48 locations
Target enrolment
to

Trials with a site in Calgary

37 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Recruiting
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT07039110Plaque Psoriasis
AbbVie
Observational
700
Calgary, Edmonton, Winnipeg, Ajax, Belleville, Hamilton, London, Markham
2025-09-09
Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
NCT07136467Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
AbbVie
Observational
2,795
Calgary, Edmonton, Fredericton, Barrie, London, Markham, Richmond Hill, Pointe-Claire
2025-09-02
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
DrugRisankizumab
AbbVie
Phase 3
120
Calgary, Edmonton, London
2025-07-28
Recruiting
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446Rheumatoid Arthritis
DrugsABBV-8736·ABBV-701·Lutikizumab·Adalimumab
AbbVie
Phase 2
180
Calgary, Sherbrooke, Saskatoon
2025-06-20
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
DrugsRisankizumab·Vedolizumab
AbbVie
Phase 3
573
Calgary, Edmonton, Barrie, Brampton, Oakville, Toronto, Montreal, Québec
2025-06-17
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Panitumumab·Leucovorin·Fluorouracil
AbbVie
Phase 2
390
Calgary, Edmonton, London, Toronto, Montreal
2025-04-24
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Calgary, Vancouver, Saint John, Halifax, London, Ottawa, Toronto, Lévis
2024-11-26
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
590
Calgary, Edmonton, Greater Sudbury, London, Vaughan, Montreal, Québec
2024-09-04
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
DrugsUpadacitinib·Dupilumab
AbbVie
Phase 3
675
Calgary, Edmonton, Vancouver, Halifax, Hamilton, Markham, Niagara Falls, Toronto
2024-08-19
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744Juvenile Psoriatic Arthritis
DrugsSkyrizi·Risankizumab·Adalimumab
AbbVie
Phase 3
40
Calgary, Vancouver, Toronto
2024-07-08
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Calgary, Edmonton, Kelowna, Fredericton, St. John's, Cobourg, Hamilton, London
2024-06-27
Recruiting
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136Atopic Dermatitis
DrugsUpadacitinib·Dupilumab
AbbVie
Phase 3
200
Calgary, Edmonton, Richmond Hill, Québec
2024-06-14
Active, closed
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275Crohn's Disease
AbbVie
Observational
1,200
Calgary, Edmonton, New Westminster, Winnipeg, Halifax, Barrie, London, Mississauga
2024-02-19
Active, closed
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
NCT06107426Parkinson's Disease (PD)
AbbVie
Observational
427
Calgary, Ottawa, Montreal, Québec
2024-01-24
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Calgary, Surrey, Winnipeg, Fredericton, Hamilton, Waterloo, Québec, Saint-Jérôme
2023-12-19
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
DrugRisankizumab
AbbVie
Phase 3
110
Calgary, Edmonton, Vancouver, London
2023-12-11
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
289
Calgary, Edmonton, Halifax, Vaughan, Montreal
2023-11-15
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
1,500
Calgary, Edmonton, Surrey, Winnipeg, Barrie, Greater Sudbury, Hamilton, Markham
2023-10-11
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
DrugUpadacitinib
AbbVie
Phase 3
1,014
Calgary, Edmonton, Winnipeg, Toronto, Sherbrooke
2023-07-25
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Calgary, Edmonton, Red Deer, Surrey, Winnipeg, St. John's, Hamilton, London
2023-06-21
Active, closed
An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
NCT05841537Crohn's Disease
AbbVie
Observational
1,019
Calgary, Edmonton, Lethbridge, Kelowna, New Westminster, Victoria, Moncton, Hamilton
2023-06-09
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab
AbbVie
Phase 3
520
Calgary, Edmonton, Surrey, Vancouver, Hamilton, Kingston, Ottawa, Toronto
2023-03-15
Active, closed
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
NCT05424562Acute Myeloid Leukemia
AbbVie
Observational
210
Calgary, Edmonton, Surrey, Vancouver, Victoria, Winnipeg, Moncton, St. John's
2022-09-07
Active, closed
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
NCT05494606Ulcerative Colitis
AbbVie
Observational
785
Calgary, Edmonton, Lethbridge, Kelowna, Moncton, Barrie, Hamilton, London
2022-08-15
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Calgary, Edmonton, New Westminster, Vancouver, Etobicoke, Ottawa, Toronto, Québec
2022-01-13
Active, closed
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
NCT05139602Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 2
210
Calgary, Winnipeg, Hamilton, Newmarket, Saint-Jérôme
2021-12-28
Recruiting
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
NCT05005403Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer
DrugsBudigalimab·Telisotuzumab Adizutecan·Bevacizumab
AbbVie
Phase 1
694
Calgary, Toronto, Montreal
2021-11-01
Active, closed
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611Crohn's Disease (CD)
DrugsSkyrizi·Risankizumab·Ustekinumab
AbbVie
Phase 3
527
Calgary, Edmonton, New Westminster, Victoria, Halifax, London, North Bay, Toronto
2020-09-30
Active, closed
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
NCT03725007Juvenile Idiopathic Arthritis (JIA)
DrugUpadacitinib
AbbVie
Phase 1
124
Calgary, Vancouver, Montreal
2019-06-24
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
DrugsPomalidomide·Venetoclax·Dexamethasone
AbbVie
Phase 3
265
Calgary, Vancouver, Halifax, Lévis
2018-10-22
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,242
Calgary, Edmonton, New Westminster, Victoria, London, North Bay, Vaughan, Lévis
2018-08-28
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
DrugUpadacitinib
AbbVie
Phase 3
1,533
Calgary, Edmonton, St. John's, Halifax, Markham, Mississauga, Oakville, Ottawa
2018-08-09
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,336
Calgary, Edmonton, New Westminster, Vancouver, Victoria, Halifax, Greater Sudbury, Hamilton
2018-04-09
Active, closed
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
NCT03314181Multiple Myeloma
DrugsBortezomib·Daratumumab·Venetoclax·Dexamethasone
AbbVie
Phase 2
156
Calgary, Edmonton, Montreal
2018-04-02
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
747
Calgary, Edmonton, New Westminster, Vancouver, Halifax, Greater Sudbury, London, North Bay
2018-03-21
Active, closed
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523Acute Myeloid Leukemia (AML)
DrugsAzacitidine·Venetoclax
AbbVie
Phase 3
443
Calgary, Vancouver, Hamilton, Ottawa, Toronto
2017-02-02
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068Ulcerative Colitis (UC)
DrugUpadacitinib
AbbVie
Phase 3
950
Calgary, Edmonton, Kelowna, Victoria, Greater Sudbury, Hamilton, Ottawa, Vaughan
2017-01-31
Rows per page Showing 1–37 of 37
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-canada/city/calgary

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 37 of those studies with a site in Calgary that also match the filters currently applied.

How many clinical trials are recruiting in Calgary?

12 of the 37 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 0 have not yet opened recruitment, 25 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Calgary), 37 studies
PhaseStudiesRecruitingShare
Phase 322659.5%
Observational8221.6%
Phase 25313.5%
Phase 1215.4%

Most active sponsors

Lead sponsors with the most studies (Calgary)
Lead sponsorStudiesRecruiting
AbbVie3712
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.